Beyond Air Approved to Initiate Clinical Study at 150 ppm Nitric Oxide with LungFit for the Treatment of Acute Viral Pneumonia Including COVID-19 - Seite 2

The LungFit^TM system is a portable device, that weighs only 20 lbs and operates with a standard electrical outlet (120-240 volts). Since NO is generated from ambient air that flows through a reaction chamber, there is an unlimited supply. The LungFit system is designed to accommodate simultaneous oxygen delivery for patients who require it via a dedicated port in the rear of the device. Beyond Air’s proprietary nitrogen dioxide (NO₂) filters are required for the system to generate and safely deliver NO. Toxic levels of NO₂ can result from high concentrations of NO without proper filtration. The filters also program the system, via an attached RFID chip, with NO concentration, flow rate and duration. The Company believes this provides flexibility for NO administration. The Company is confident that respiratory therapists (RTs) can easily be trained to use and manage the system. If multiple patients are treated in the same facility, one RT could manage multiple systems simultaneously, with each system potentially treating up to four patients per day. Filters are single patient use and there are no special requirements for disposal. Alarms monitor system performance.

About Beyond Air, Inc.
Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, the LungFit, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs of ventilated and non-ventilated patients for the potential treatment of a variety of pulmonary diseases. The LungFit can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary LungFit system in clinical trials for the treatment of severe lung infections such as SARS-CoV-2, bronchiolitis and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system, separate from the LungFit, to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.